



11 May 2021

(21-4027)

Page: 1/1

**Council for Trade-Related Aspects of
Intellectual Property Rights**

Original: Spanish

NOTIFICATION UNDER THE AMENDED TRIPS AGREEMENT

**NOTIFICATION OF NEED TO IMPORT PHARMACEUTICAL PRODUCTS
UNDER THE SPECIAL COMPULSORY LICENSING SYSTEM**

Notifying Member(s)	PLURINATIONAL STATE OF BOLIVIA
Product(s) needed	An estimated 15 million doses of COVID-19 vaccines. In particular, the intention is to import the vaccine, Ad26.COV2.S, a replication-incompetent adenovirus type 26 (AD16) vectored vaccine encoding a stabilized variant of the S protein of SARS-Cov-2. The Plurinational State of Bolivia reserves the right to import other vaccines.
Establishment of no or insufficient manufacturing capacities in the pharmaceutical sector	<input checked="" type="checkbox"/> Member currently has no manufacturing capacities in the pharmaceutical sector. <input type="checkbox"/> Member has found that its manufacturing capacity in the pharmaceutical sector is insufficient to meet its needs for the needed pharmaceutical product(s).
Information on how the lack of (sufficient) manufacturing capacity in the pharmaceutical sector was established	The Plurinational State of Bolivia has found that it has no manufacturing capacities in the pharmaceutical sector for COVID-19 vaccines, including the Ad26.COV2.S vaccine.
Is/are the product(s) needed protected by patent in the territory?	<input type="checkbox"/> No. <input type="checkbox"/> Yes. <input checked="" type="checkbox"/> To be determined. Should the patents for the products needed have been applied for or granted, the Plurinational State of Bolivia intends to grant compulsory licenses, in accordance with Articles 31 and 31bis of the TRIPS Agreement.
Submission date of notification	10 May 2021